|1.||Mekhail, Tarek: 1 article (04/2007)|
|2.||Creaven, Patrick J: 1 article (04/2007)|
|3.||Tanaka, Kazushige: 1 article (04/2007)|
|4.||Javle, Milind M: 1 article (04/2007)|
|5.||Ikeda, Minoru: 1 article (04/2007)|
|6.||Yamada-Sawada, Takuko: 1 article (04/2007)|
|7.||Sullivan, Daniel M: 1 article (04/2007)|
|8.||Yano, Yoshitaka: 1 article (04/2007)|
|9.||Bukowski, Ronald: 1 article (04/2007)|
|10.||Kambayashi, Yoshikaze: 1 article (04/2007)|
04/01/2007 - "A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors."
04/01/2007 - "Patients had tumor biopsies before and after S-3304 administration and were also evaluated for response and survival. "
04/01/2007 - "The aims of this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and intratumoral MMP inhibitory activity of single-agent S-3304 in advanced and refractory solid tumors. "
06/01/2005 - "Most commonly reported adverse events in the multiple treatments with S-3304 were headache and somnolence. "
06/01/2005 - "Adverse events reported in the multiple dose treatment with S-3304 or placebo were mostly of mild severity, except for two episodes of moderate headache and two episodes of moderate myalgia. "